Bristol Myers Squibb is issuing corporate bonds to fund its acquisitions of Karuna Therapeutics and RayzeBio. The company has received orders exceeding $85 billion for the bond sale, with various notes totaling $13 billion being priced.
Merger Monthly: FTC Works Toward Expanding Pharma Deal Analysis With Looks at AbbVie/Cerevel, AstraZeneca/Icosavax and Bristol Myers Squibb/Karuna $ABBV $ACI $AMED $AMGN $AZN $BMY $CERE $CHH $CPB $CPRI $ICVX $KR $KRTX $PFE $SOVO $TPR $UNH h/t @jbliss1987 https://t.co/Rj7NNCmMGG
$BMY 🇺🇸 Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes $500mm FRN '26 $1.0B 4.950% '26 $1.0B 4.900% '27 $1.75B 4.900% '29 $1.25 5.100% '31 $2.5B 5.200% '34 $500mm 5.500% '44 $2.75B 5.550%' 54 $1.75B 5.650% '64 https://t.co/JNa3GmVCCs https://t.co/KLART6JymS
Bristol Myers sees over $85 billion of demand for M&A bond sale https://t.co/1RhzwgGcKj via @Business
Bristol Myers has gathered orders exceeding $85 billion for its corporate bond sale to help finance its acquisitions of Karuna Therapeutics and RayzeBio, according to people with knowledge of the matter. https://t.co/vjGiYiRcwH via @markets $BMY
Bristol Myers has gathered orders exceeding $85 billion for its corporate bond sale to help finance its acquisitions of Karuna Therapeutics and RayzeBio, according to people with knowledge of the matter. https://t.co/yILQ3MaXxI
Bristol Myers Squibb is selling corporate bonds to help finance its acquisitions of Karuna Therapeutics and RayzeBio https://t.co/zB5Lmq1maH